Pluri Takes 50% of ZEO and Raises $1.0M at $1.10; Chairman Buys EIB Loan
PLUR sits 47% above its 52-week low of $0.85.
Summary
Pluri signed definitive terms to license its regenerative medicine portfolio to ZEO ScientifiX for 50% of ZEO plus board control, raised $1.0M in a $1.10-per-share private placement, and saw its chairman buy the ~US$27.5M EIB loan at a discount.
Key Events · M&A and Partnerships · PLUR
-
Pluri to Own 50% of ZEO
ZEO issues Pluri 41% of its issued and outstanding share capital plus 50 Series D Preferred Shares carrying 51% of ZEO votes; after the 4% secondary sale and 5% issuance, Pluri holds 50% of ZEO and can designate 4 of 7 directors while it holds at least 25%.
-
$1.0M Placement at $1.10
Two healthcare/biotech investment firms each buy 454,546 shares at US$1.10 plus 454,546 warrants at US$1.30 (100% coverage, exercisable after six months, five-year term) — 909,092 shares and 909,092 warrant shares in aggregate, expected to close on or before October 30, 2026.
-
Pluri Issues 9% of Its Shares
Pluri issues 4% of its common shares to ZEO selling shareholders and 5% to ZEO at closing, plus a further 5% if ZEO's 30-day average price reaches US$5.50.
-
Chairman Buys ~US$27.5M EIB Loan
Chutzpah Holdings, beneficially owned by chairman Alexandre Weinstein, bought the EIB loan (US$27.5M outstanding including accrued interest as of September 30, 2026) at a negotiated discounted price; guarantees are unchanged and settlement terms are not yet agreed.
Analysis · PLUR · Life Sciences
Pluri is converting its regenerative medicine platform into an operating stake: it hands ZEO an exclusive U.S. license to its product portfolio and ends up owning 50% of ZEO, with 4 of 7 board seats and preferred stock carrying 51% of ZEO's votes. That is a real strategic shift for a company whose 10-K, as previously disclosed, carried going-concern doubt and less than three months of cash runway. The $1.0M placement at $1.10 per share (versus $1.25 today) is small but priced above the August 2026 registered direct, and the warrants at $1.30 add a further 909,092 shares of overhang. The bigger balance-sheet item is the EIB loan: chairman Alexandre Weinstein's Chutzpah Holdings bought the ~US$27.5M loan from the EIB at a negotiated discount, which does not reduce the obligation but puts the largest creditor in friendly hands and opens settlement talks. Closing of the ZEO deal is conditional on IIA approval, valuations, employment agreements and resolution of the EIB default, with a 90-day outside date.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.4% of the 908 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLUR was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.1M. The 52-week trading range was $0.85 to $4.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.